SCHEMBL4925960

SCHEMBL4925960

[c]1nccc2cc3ccccc3nc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.54
HPGD P15428 3/20 0.54
GLA P06280 2/20 0.54
MAPT P10636 2/20 0.54
ACHE P22303 1/20 0.54
HTR3A P46098 1/20 0.41
KDM4E B2RXH2 5/20 0.37
GAA P10253 3/20 0.37
TDP1 Q9NUW8 1/20 0.37
STAT3 P40763 1/20 0.37
NQO2 P16083 1/20 0.37
KMT2A Q03164 3/20 0.36
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
PTBP1 P26599 1/20 0.36
RCE1 Q9Y256 1/20 0.36
PDE10A Q9Y233 1/20 0.35
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26373 0.73 ALDH1A1 (0.56) ALDH1A1HPGDGLAMAPTACHE
Acridine SCHEMBL4972293 0.72 ALDH1A1 (1.00) ALDH1A1HPGDGLAMAPTACHE
Acridine SCHEMBL3045498 0.72 ALDH1A1 (1.00) ALDH1A1HPGDGLAMAPTACHE
Acridine SCHEMBL8339 0.72 ALDH1A1 (1.00) ALDH1A1HPGDGLAMAPTACHE
Acridine SCHEMBL1772714 0.72 ALDH1A1 (1.00) ALDH1A1HPGDGLAMAPTACHE
Acridine SCHEMBL29352289 0.72 ALDH1A1 (1.00) ALDH1A1HPGDGLAMAPTACHE
SCHEMBL4922951 0.72 ALDH1A1 (0.54) ALDH1A1HPGDGLAMAPTACHE
SCHEMBL3141049 0.71 ALDH1A1 (0.41) ALDH1A1HPGDGLAMAPTACHE
Anthracene SCHEMBL9879830 0.70 MAPT (0.94) ALDH1A1HPGDGLAMAPTACHE
Acridine SCHEMBL1551975 0.70 ALDH1A1 (0.94) ALDH1A1HPGDGLAMAPTACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255175-A1 Anti-cancer agents, compositions and methods of treating cancers ACB, LLC 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255175-A1 Anti-cancer agents, compositions and methods of treating cancers HCCS, EPOR, RAD51 ALDH1A1 2244/4885HPGD 973/4885GLA 1357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.